Multigene assays and isolated tumor cells for early breast cancer treatment: Time for bionetworks

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1187-1195

  Roukos, Dimitrios H ^a   Ziogas, Dimosthenis E ^a   Katsios, Christos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

breast cancer; cancer genomes; multigene assays; node negative; systems biology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ASSAY; BREAST CANCER; CANCER GENETICS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MULTIGENE FAMILY; REVIEW; SENTINEL LYMPH NODE; TREATMENT PLANNING; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL SEPARATION; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MULTIGENE FAMILY; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956247826     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.91     Document Type: Review

References (71)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. DOI: doi: 10.3322/caac.20073 (2010) (Epub ahead of print).
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717 (2005).
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).
4. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
5. Green FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual (6th Edition). American Joint Commission on Cancer, IL, USA (2002).
6. De Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 361(7), 653-663 (2009).
7. Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med. 361, 1994-1995 (2009).
8. Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann. Surg. Oncol. 14(12), 3378-3384 (2007).
9. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 354, 896-900 (1999).
10. De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: revaluation with longer follow-up. Br. J. Cancer 66, 523-527 (1992).
11. Tan LK, Giri D, Hummer AJ et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J. Clin. Oncol. 26, 1803-1809 (2008).
12. Colleoni M, Rotmensz N, Peruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J. Clin. Oncol. 23, 1379-1389 (2005).
13. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
14. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
15. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-18412 (2003).
16. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
17. Van de Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
18. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
19. O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N. Engl. J. Med. 355(6), 615-617 (2006).
20. Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol. 27(8), 1337-1338 (2009).
21. Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA 299(13), 1605-1606 (2008).
22. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
23. Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. Prognosis of the upper limb following surgery and radiation for breast cancer. Breast Cancer Res. Treat. 110(1), 19-37 (2008).
24. National Comprehensive Cancer Network. Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network, PA, USA (2009).
25. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 27(34), 5700-5706 (2009).
26. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/ amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27(34), 5693-5699 (2009).
27. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006).
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
29. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
30. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2/neu positive early breast cancer patients. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006.
31. Viani G, Afonso S, Stefano E et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7, 153 (2007).
32. Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther. 10(2), 123-128 (2010).
33. Burstein HJ, Souter I, D'Alessandro HA, Sgroi DC. Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N. Engl. J. Med. 361(7), 699-707 (2009).
34. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
35. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002).
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
37. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231 (2007).
38. Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn. 9(3), 227-229 (2009).
39. Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn. 9(3), 217-221 (2009).
40. Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer 46, 1307-1318 (1980).
41. Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front. Biosci. 13, 71-84 (2008).
42. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
43. Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
44. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
45. Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
46. Snyder M, Weissman S, Gerstein M. Personal phenotypes to go with personal genomes. Mol. Syst. Biol. 5, 273 (2009).
47. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009).
48. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
49. Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature 463(7283), 899-905 (2010).
50. Bastiaens P. Systems biology: when it is time to die. Nature 459(7245), 334-335 (2009).
51. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
52. Bohman T. Mathematics. Emergence of connectivity in networks. Science 323(5920), 1438-1439 (2009).
53. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
54. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
55. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
56. Ledford H. Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010).
57. The human genome at ten. Nature 464(7289), 649-650 (2010).
58. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
59. Roukos DH. Radiation therapy for breast cancer. N. Engl. J. Med. 360(13), 1362 (2009).
60. Roukos DH. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J. Clin. Oncol. 28(17), e279-e280 (2010).
61. Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol. 16(3), 772-773 (2009).
62. Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the 'Gordian Knot'? Ann. Surg. Oncol. 16(3), 774-775 (2009).
63. Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol. 16(7), 1771-1782 (2009).
64. Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev. Anticancer Ther. 9(4), 389-392 (2009).
65. Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann. Surg. Oncol. 16(4), 795-798 (2009).
66. Collins F. Has the revolution arrived? Nature 464(7289), 674-675 (2010).
67. Venter JC. Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
68. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
69. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomarkers Med. 4(4), DOI: 110.2217/BMM.10.70 (2010) (In press).
70. Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Per. Med. 7(4), 347-350 (2010).
71. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).